IgA Nephropathy clinical trials at University of California Health

3 research studies open to eligible people

Showing trials for

  • Atrasentan in Patients With IgA Nephropathy

    open to eligible people ages 18 years and up

    The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

    at UCLA UCSF

  • Atrasentan in Patients With Proteinuric Glomerular Diseases

    open to eligible people ages 18 years and up

    The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

    at UCLA

  • Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the safety and efficacy of OMS721 in patients with IgA nephropathy. The study will assess proteinuria by 24-hour urine protein excretion (UPE) in g/day at 36 weeks from beginning of treatment.

    at UCLA

Our lead scientists for IgA Nephropathy research studies include .

Last updated: